AG真人官方

Equifax Q2 2025 (10-Q) snapshot

• Revenue up 7% YoY to $1.54 bn; first-half revenue up 6% to $2.98 bn.
• Operating income rose 10% to $311 m; margin improved 20.2% vs 19.7%.
• Diluted EPS $1.53 (+17%); YTD EPS $2.59 (+12%).
• Segment growth: Workforce Solutions +8% (Verification Services +10%, Employer Services -2%); USIS +9%; International +4% with strength in Europe and Latin America.
• Cost of services +5%; SG&A +9% on higher litigation & people costs; D&A +8% as cloud investment amortisation rises.
• Operating cash flow YTD $585 m (+12%); capex $223 m (-13%), reflecting tapering cloud spend.
• Balance sheet: cash $189 m; total debt $4.92 bn (-$116 m YTD) though short-term borrowings increased to $847 m.
• Capital returns: dividend raised 28% to $0.50/quarter; new $3 bn buyback authorisation with $127 m repurchased in Q2 (capacity $2.9 bn).
• Effective tax rate 26.3%; $6 m restructuring tied to cloud migration; no acquisitions closed in H1.
• Outlook notes macro uncertainty and expected 2025 US mortgage softness, but management targets continued organic growth via new analytics and cloud-native data assets.

On 22 July 2025 AstraZeneca (AZN) filed a Form 6-K detailing a $50 billion capital plan to be executed in the United States by 2030. Management expects the outlay to help lift Total Revenue to $80 billion by 2030, with 鈮�50% generated in the US (vs. 42% in 2024).

The centre-piece is a multi-billion-dollar drug-substance facility in Virginia鈥攖he company鈥檚 largest single-site investment鈥攄esigned to manufacture weight-management and metabolic candidates such as oral GLP-1, baxdrostat and oral PCSK9. The plant will use AI, automation and advanced analytics to optimise production.

Additional funds will expand R&D hubs (Gaithersburg MD, Cambridge MA), build cell-therapy sites (Rockville MD, Tarzana CA) and enlarge manufacturing footprints in Indiana and Texas. The company expects the programme to create tens of thousands of direct and indirect US jobs, reinforce the domestic supply chain and accelerate the launch of 20 new medicines this decade.

The disclosure signals an aggressive push to scale US operations, increase market share in chronic-disease therapeutics and align with reshoring policies. No incremental financing details or earnings guidance were provided.

SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) filed seven Post-Effective Amendments on Form S-8 to deregister all unsold shares previously registered for issuance under its 2019 employee equity plans. The action follows the closing of its merger with Merck KGaA, Darmstadt, Germany on 1 July 2025, under which SpringWorks became a wholly owned subsidiary of Merck through EMD Holdings Merger Sub, Inc.

The amendments cover the following historical S-8 registrations:

• Reg. Nos. 333-234365, 333-237350, 333-253531, 333-262996, 333-270096, 333-277380 and 333-285076.
• In aggregate, these filings had registered tens of millions of common shares for the 2019 Stock Option & Incentive Plan, the Amended & Restated 2019 Equity Incentive Plan and the 2019 Employee Stock Purchase Plan.

Because the company is now private, SpringWorks has terminated all offerings under these plans. Consistent with undertakings in each registration statement, any securities that remained unsold as of the merger date are withdrawn from registration. The filing is signed on behalf of the company by Secretary Michael MacDougall and relies on Rule 478 of the Securities Act to omit additional signatures.

The amendments are largely administrative, signalling the end of SpringWorks鈥� status as an independent public issuer and the cessation of share issuance under its legacy equity compensation and ESPP programmes.